Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 86

Sort by

Sort Order Select

Journal Articles

Idiopathic multicentric castleman disease - tafro: A potentially curable disease?

Lu Zhang, Jiaying Ge, Siyuan Li, Liangshun You, Jian Li

Blood (2025) 146 (Supplement 1): 1230.

https://doi.org/10.1182/blood-2025-1230

Published: 2025

Journal Articles

Prognostic significance of pulmonary involvement in idiopathic multicentric castleman disease

Yu-han Gao, Jia-min Zhou, Cong-Wei Jia, Siyuan Li, Yue Dang, Lu Zhang, Jian Li

Blood (2025) 146 (Supplement 1): 1229.

https://doi.org/10.1182/blood-2025-1229

Published: 2025

Journal Articles

Idiopathic multicentric castleman disease unresponsive to one IL-6 inhibitor may respond to another IL-6 inhibitor

Kayla McHugh, Yuan Huang, Bridget Austin, Larissa Borys, Abiola Irvine, Daisy Alapat, Adam Bagg, Amy Chadburn, Mary Jo Lechowicz, Megan Lim, Gordan Srkalovic, Frits van Rhee, David Fajgenbaum, Lu Zhang, Joshua Brandstadter

Blood (2025) 146 (Supplement 1): 1228.

https://doi.org/10.1182/blood-2025-1228

Published: 2025

Journal Articles

Is 'severe’ imcd-IPL really severe?

Siyuan Li, Yu-han Gao, Yue Dang, Jian Li, Lu Zhang

Blood (2025) 146 (Supplement 1): 1816.

https://doi.org/10.1182/blood-2025-1816

Published: 2025

Journal Articles

Systematic analysis of gene mutations in Chinese multiple myeloma patients.

Jinhua Wang, Hongxiao Han, Qun Li, Chi Ma, Hao Cai, Linyu Cai, Kaini Shen, Fei Zhao, Jian Xu, Lu Zhang, Bo Zhang, Jian Li, Chunyan Sun

Blood (2025) 146 (Supplement 1): 3989.

https://doi.org/10.1182/blood-2025-3989

Published: 2025

Journal Articles

First-line selinexor plus R-CHOP for high-risk GCB-subtype diffuse large B-cell lymphoma: A multi-center, single-arm, Phase II trial

Hang Yang, Peng SUN, Panpan LIU, Yu Wang, Hui Zhou, Ying Lu, Lu Zhang, Keshu Zhou, Zhiming Li

Blood (2025) 146 (Supplement 1): 1922.

https://doi.org/10.1182/blood-2025-1922

Published: 2025

Journal Articles

Efficacy and safety of polatuzumab vedotin–based regimens in newly diagnosed diffuse large B-cell lymphoma: A single-center retrospective study

Taiyuan Zhang, Yingying Wu, Zhipeng Cheng, Ao Zhang, Lin Liu, Lu Zhang, Danying Liao, Wei Xie, Fang Liu, Guohui Cui, Yu Hu, Heng Mei, Jun Fang

Blood (2025) 146 (Supplement 1): 7207.

https://doi.org/10.1182/blood-2025-7207

Published: 2025

Journal Articles

Impact of systemic high-dose MTX and BTK inhibitors on outcomes in vitreoretinal lymphoma: A multicenter retrospective analysis

Jing Gao, Lu Zhang, Liang Wang

Blood (2025) 146 (Supplement 1): 5467.

https://doi.org/10.1182/blood-2025-5467

Published: 2025

Journal Articles

PRKRA associated with NF-κB activation in pulmonary involvement of idiopathic multicentric castleman disease

Yu-han Gao, Cong-Wei Jia, Zhi-yuan Li, Jia-min Zhou, Zhen-huan Tian, Siyuan Li, Yue Dang, Lu Zhang, Jian Li

Blood (2025) 146 (Supplement 1): 4784.

https://doi.org/10.1182/blood-2025-4784

Published: 2025

Journal Articles

An open-label Phase II trial of VDJ-001, a high-affinity IL-6R antagonist antibody, for the treatment of patients with idiopathic multicentric castleman disease

Lu Zhang, Rui Chen, Yujun Dong, Qin Wang, Liangming Ma, Jun Zhang, Zi-qiang Li, Jian Li

Blood (2025) 146 (Supplement 1): 4787.

https://doi.org/10.1182/blood-2025-4787

Published: 2025

Journal Articles

Germline osmr mutation drives familial unicentric castleman disease with osteosclerosis

Miaoyan Zhang, Yan-ting Liu, Yue Dang, Yu-han Gao, Siyuan Li, Lu Zhang, Jian Li

Blood (2025) 146 (Supplement 1): 3536.

https://doi.org/10.1182/blood-2025-3536

Published: 2025

Journal Articles

Relationship between changes in quality of life and social function and treatment response in patients with idiopathic multicentric castleman disease: A single-center observational longitudinal survey

Jia Chen, Lu Zhang, Jian Li

Blood (2025) 146 (Supplement 1): 8061.

https://doi.org/10.1182/blood-2025-8061

Published: 2025

Journal Articles

Efficacy and Safety of Orelabrutinib in Relapsed/Refractory Idiopathic Multicentric Castleman Disease: A Single-Center, Retrospective Study

Yuhan Gao, Siyuan Li, Yue Dang, Minghui Duan, Jian Li, Lu Zhang

Blood (2024) 144 (Supplement 1): 1656.

https://doi.org/10.1182/blood-2024-204570

Published: 2024

Journal Articles

Asymptomatic Multicentric Castleman Disease: A Potential Early Stage of Idiopathic Mcd

Blood (2024) 144 (Supplement 1): 4417.

https://doi.org/10.1182/blood-2024-204513

Published: 2024

Journal Articles

TRIM28 Facilitates Chronic Myeloid Leukemia Progression By Enhancing Sumoylation and Stability of BCR-ABL

Lu Zhang, Xuefeng Wang, Dongmei Hu, Shijie Li, Mingshan Sun, Qian Liu, Huimin Feng, Minran Zhou, Chen Chunyan, Huan Zhou, Sai Ma

Blood (2024) 144 (Supplement 1): 1355.

https://doi.org/10.1182/blood-2024-199484

Published: 2024

Journal Articles

Efficacy and Safety of Single-Dose Versus Split-Dose Mecapegfilgrastim with Etoposide for Autologous Peripheral Blood Stem Cell Mobilization: A Prospective, Randomized Clinical Trial

Blood (2024) 144 (Supplement 1): 4855.

https://doi.org/10.1182/blood-2024-202870

Published: 2024

Journal Articles

Quality of Life after Idiopathic Multicentric Castleman Disease in China: A Cross-Sectional, Multi-Center Survey of Patient Reported Outcome and Caregiver Reported Outcome

Jia Chen, Miaoyan Zhang, Yuhan Gao, Lu Zhang, Jian Li

Blood (2024) 144 (Supplement 1): 7852.

https://doi.org/10.1182/blood-2024-210512

Published: 2024

Journal Articles

Potential Opportunity for Drug Discontinuation in Idiopathic Multicentric Castleman Disease: Evaluating the Efficacy of TCP Protocol

Yue Dang, Yuhan Gao, Siyuan Li, Lu Zhang, Jian Li

Blood (2024) 144 (Supplement 1): 6310.

https://doi.org/10.1182/blood-2024-206712

Published: 2024

Journal Articles

Residential Economic and Racial Segregation Is Associated with Acuity and Severity of Pediatric Leukemia at Presentation

Xu Ji, Rebecca Williamson Lewis, Tarun Jain, Lu Zhang, Sharon M. Castellino

Blood (2024) 144 (Supplement 1): 3735.

https://doi.org/10.1182/blood-2024-205951

Published: 2024

Journal Articles

Tafro Syndrome without Pathological Evidence Consistent with Castleman Disease: A Subtype of Tafro or a Distinct Disease Entity?

Siyuan Li, Yuhan Gao, Yue Dang, Lu Zhang, Jian Li

Blood (2024) 144 (Supplement 1): 6298.

https://doi.org/10.1182/blood-2024-204501

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Idiopathic multicentric castleman disease - tafro: A potentially curable disease?

Prognostic significance of pulmonary involvement in idiopathic multicentric castleman disease

Idiopathic multicentric castleman disease unresponsive to one IL-6 inhibitor may respond to another IL-6 inhibitor

Is 'severe’ imcd-IPL really severe?

Systematic analysis of gene mutations in Chinese multiple myeloma patients.

First-line selinexor plus R-CHOP for high-risk GCB-subtype diffuse large B-cell lymphoma: A multi-center, single-arm, Phase II trial

Efficacy and safety of polatuzumab vedotin–based regimens in newly diagnosed diffuse large B-cell lymphoma: A single-center retrospective study

Impact of systemic high-dose MTX and BTK inhibitors on outcomes in vitreoretinal lymphoma: A multicenter retrospective analysis

PRKRA associated with NF-κB activation in pulmonary involvement of idiopathic multicentric castleman disease

An open-label Phase II trial of VDJ-001, a high-affinity IL-6R antagonist antibody, for the treatment of patients with idiopathic multicentric castleman disease

Germline osmr mutation drives familial unicentric castleman disease with osteosclerosis

Relationship between changes in quality of life and social function and treatment response in patients with idiopathic multicentric castleman disease: A single-center observational longitudinal survey

Efficacy and Safety of Orelabrutinib in Relapsed/Refractory Idiopathic Multicentric Castleman Disease: A Single-Center, Retrospective Study

Asymptomatic Multicentric Castleman Disease: A Potential Early Stage of Idiopathic Mcd

TRIM28 Facilitates Chronic Myeloid Leukemia Progression By Enhancing Sumoylation and Stability of BCR-ABL

Efficacy and Safety of Single-Dose Versus Split-Dose Mecapegfilgrastim with Etoposide for Autologous Peripheral Blood Stem Cell Mobilization: A Prospective, Randomized Clinical Trial

Quality of Life after Idiopathic Multicentric Castleman Disease in China: A Cross-Sectional, Multi-Center Survey of Patient Reported Outcome and Caregiver Reported Outcome

Potential Opportunity for Drug Discontinuation in Idiopathic Multicentric Castleman Disease: Evaluating the Efficacy of TCP Protocol

Residential Economic and Racial Segregation Is Associated with Acuity and Severity of Pediatric Leukemia at Presentation

Tafro Syndrome without Pathological Evidence Consistent with Castleman Disease: A Subtype of Tafro or a Distinct Disease Entity?

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only